U.S. markets closed

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0600-0.0900 (-2.17%)
At close: 4:00PM EDT
4.0700 +0.01 (0.25%)
After hours: 05:19PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close4.1500
Open4.1200
Bid4.0100 x 1200
Ask4.0700 x 900
Day's Range4.0370 - 4.1350
52 Week Range1.9800 - 10.3000
Volume155,053
Avg. Volume1,036,348
Market Cap61.013M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • US Patent Office Grants Foundational Pharmacogenomic Patent
    GlobeNewswire

    US Patent Office Grants Foundational Pharmacogenomic Patent

    MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has been granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis’. The patent application was submitted in 2016, building on a patent family dating back to 2001 and was recently granted to Genetic Technologies and demonstrates an important addition to Genetic Technologies p

  • Genetic Technologies’ COVID-19 Risk Test Now Available in US through Partnership with Infinity BiologiX
    GlobeNewswire

    Genetic Technologies’ COVID-19 Risk Test Now Available in US through Partnership with Infinity BiologiX

    Test improves COVID-19 prevention and management capabilities for employers, governments, and public health decision makersKey Highlights: Gene’s COVID-19 Risk Test released for sale in the US through IBXDesigned to predict disease severity to assist in informing decisions about disease risk, treatment options and vaccination prioritiesIBX have extensive experience with large-scale COVID testing with processing capacity for 100,000 risk tests per dayCOVID-19 Risk Test is applicable for men and women ages 18 years and over MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI-driven preventative health business, is pleased to announce the official launch of its COVID-19 Serious Disease Risk Test (‘COVID-19 Risk Test’) in the US through its partnership with Infinity BiologiX LLC (‘IBX’). IBX will produce, distribute, and sell GENE’s test across its established network, https://ibx.bio/services/covid-19-severity-test/ Designed to predict disease severity using genetic and clinical information the test provides a risk score to help individuals aged 18 years and over to understand their personal risk of contracting a serious case of COVID-19. In addition, employers, governments, and other public health entities may use the data to make informed decisions about disease risk, treatment options, and vaccination priorities. This will assist in guiding proactive steps to minimize disease exposure and manage the pandemic in the weeks and months ahead. “This is a fantastic milestone for our team,” commented Simon Morriss, CEO of Genetic Technologies. “Our COVID-19 Risk Test is a crucial product that will provide individuals with the ability to understand their personal risk associated with contracting a serious case of this disease. Alongside existing treatment options and vaccines, we believe this test will enable more insightful decisions for states, workplaces and individuals on pathways forward in managing this pandemic.” IBX is a market-disrupting central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas. Extensive experience with large-scale COVID testing and sample processing made IBX a clear choice for this endeavor. Through its labs in New Jersey and Minnesota and with partner organizations around the US, the company is able to process over 100,000 risk tests per day. IBX launched its COVID-19 saliva-test in May 2020, after receiving FDA Emergency Use Authorization. It was the first test to utilize saliva as the primary biomaterial for SARS-CoV-2, and IBX subsequently became the first company to offer an at-home collection with this approach. Developed by GENE, the COVID-19 risk test will be distributed and sold in the US by IBX, released under GENE’s ‘powered by GeneType’ brand, and is applicable to men and women ages 18 and up. IBX will determine sales and end consumer pricing structure for the risk test and will produce, distribute, and market it in the US. Investor Relations (AUS) Stephanie Ottens Market Eye M: +61 434 405 400 E: stephanie.ottens@marketeye.com.au Investor Relations and Media (US) Dave Gentry1 800 RED CHIP (733 2447) Cell: 407 491 4498 E: dave@redchip.com About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is an Australian based diversified molecular diagnostics company. GENE offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The company’s lead products, GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer, are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products based on a world leading technology platform created over the past 10 years. For more information, please visit www.genetype.com About Infinity BiologiX LLC: Infinity BiologiX (IBX) is a market-disrupting central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas. IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. For more information, visit www.ibx.bio Forward-Looking Statements This press release may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

  • Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
    GlobeNewswire

    Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

    MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today announced an interview with Simon Morriss, CEO, will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes across the United States. In the exclusive interview, Mr. Morriss discusses the Company’s upcoming milestones, updates on the company’s lead risk assessment products, GeneType for Breast Cancer, for non-hereditary breast cancer and GeneType for Colorectal Cancer, as well as their Covid19 Risk Assessment test. Mr. Morriss also discusses the company’s developing pipeline of risk assessment products and commercialization plans. To view the interview segment, please visit: https://youtu.be/-o-2YWJ7FyU “The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. For more information, please visit www.gtglabs.com Investor Relations (AUS)Investor Relations and Media (US)Stephanie OttensDave GentryMarket Eye1 800 RED CHIP (733 2447)M: +61 434 405 400Cell: 407 491 4498E: stephanie.ottens@marketeye.com.auE: dave@redchip.com